

CITATION REPORT

List of articles citing

Hydroxychloroquine-induced cardiomyopathy and heart failure in twins

DOI: 10.21037/jtd.2017.12.66

Journal of Thoracic Disease, 2018, 10, E70-E73.

Source: <https://exaly.com/paper-pdf/69945399/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Hydroxychloroquine. <i>Reactions Weekly</i> , 2018 , 1691, 153-153	0	
20	Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity. <i>ESC Heart Failure</i> , 2019 , 6, 1326-1330	3.7	5
19	Nanomedicine strategies to target coronavirus. <i>Nano Today</i> , 2020 , 35, 100961	17.9	28
18	Antimalarial Agents. 2021 , 234-244.e4		1
17	Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?. <i>Phytomedicine</i> , 2021 , 85, 153396	6.5	15
16	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. <i>Rheumatology International</i> , 2021 , 41, 1189-1202	3.6	5
15	A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021 , 1-14	3.6	0
14	Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. <i>Current Cardiology Reviews</i> , 2021 , 17, 319-327	2.4	2
13	A review of cardiovascular involvements associated with medications used to treat COVID-19 infection. <i>Cor Et Vasa</i> , 2021 , 63, 359-363	0.3	
12	Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases. <i>Kidney Diseases (Basel, Switzerland)</i> , 2021 , 5, 1-10	3.3	0
11	Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy. <i>PLoS ONE</i> , 2020 , 15, e0239675	3.7	4
10	Evaluation and follow-up of pediatric COVID-19 in terms of cardiac involvement: A scientific statement from the Association of Turkish Pediatric Cardiology and Pediatric Cardiac Surgery. <i>Anatolian Journal of Cardiology</i> , 2020 , 24, 13-18	0.8	5
9	COVID-19 Treatment: The Race Against Time. <i>Electronic Journal of General Medicine</i> , 2020 , 17, em227	2.1	14
8	A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. <i>Electronic Journal of General Medicine</i> , 2020 , 17, em251	2.1	7
7	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <i>Frontiers in Pharmacology</i> , 2020 , 11, 597985	5.6	13
6	Hydroxychloroquine as Oral Antidiabetic Agent During Coronavirus Pandemic. <i>Global Journal of Infectious Diseases and Clinical Research</i> , 2020 , 6, 006-008	0.2	
5	I. Cloroquina / hidroxiclороquina y azitromicina. Revisi3n narrativa de seguridad. 2020 , 2, 71-82		

4 The assessment of similarity vectors of fingerprint and UMLS in adverse drug reaction prediction.

3 Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. *Therapeutic Advances in Musculoskeletal Disease*, **2022**, 14, 1759720X211073001 3.8 5

2 Hydroxychloroquine-Induced Dilated Cardiomyopathy: A Case Report. **2022**, 1,

1 Nebulizer spray delivery of phytopharmaceutical nanosuspension via oral and nasal route. **2023**, 437-457 0